Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Liminatus Pharma ( (LIMN) ) has provided an update.
Liminatus Pharma completed a business combination with IRIS Acquisition Corp. in May 2025, with its shares now trading on the Nasdaq Global Market under the ticker symbol ‘LIMN.’ The company is advancing its proprietary CD47 blockade, IBA101, which aims to improve the safety profile of cancer treatments by overcoming issues like anemia and thrombocytopenia associated with first-generation CD47 antibodies. Liminatus plans to leverage partnerships with major pharmaceutical companies and aims to expand its market potential by combining CD47 blockade with PD-1/PD-L1 inhibitors, potentially enhancing antitumor activity by at least 10%.
More about Liminatus Pharma
Liminatus Pharma is an immunotherapy company focused on developing a CD47-blocking antibody for treating solid tumors. The company is preparing for an FDA Phase I clinical trial and plans to expand its pipeline by in-licensing CAR-T cell therapeutics and companion diagnostic technologies.
Average Trading Volume: 301,370
Technical Sentiment Signal: Strong Buy
Current Market Cap: $375.4M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.